Macro Group Pharmaceuticals (Macro Capital) S.A.E (EGX:MCRO)
Egypt
· Delayed Price · Currency is EGP 2.120
+0.030 (1.44%)
At close: Jun 25, 2025
EGX:MCRO Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 644.82 | 519.97 | 526.01 | 729.61 | 594.26 | 430.5 |
| Revenue Growth (YoY) | 49.84% | -1.15% | -27.91% | 22.78% | 38.04% | - |
| Cost of Revenue | 237.07 | 196.85 | 230.36 | 167.97 | 120.39 | 92.36 |
| Gross Profit | 407.75 | 323.12 | 295.65 | 561.64 | 473.87 | 338.14 |
| Selling, General & Admin | 296.62 | 274.82 | 353.03 | 314.18 | 256.02 | 155.56 |
| Other Operating Expenses | 0.32 | 0.59 | 26.57 | 9.96 | 13.73 | -2.02 |
| Operating Expenses | 301.2 | 311.09 | 478.04 | 327.29 | 270.25 | 156.6 |
| Operating Income | 106.55 | 12.03 | -182.39 | 234.35 | 203.62 | 181.55 |
| Interest Expense | -46.36 | -46.6 | -29.48 | -13.48 | -8.15 | -3.16 |
| Interest & Investment Income | 6.5 | 5.77 | 1.98 | 2.8 | 1.06 | 1.82 |
| Currency Exchange Gain (Loss) | -9.08 | -9.39 | 14.23 | 3.68 | -0.06 | 0.04 |
| Other Non Operating Income (Expenses) | - | -4.65 | -49.95 | - | - | -2.57 |
| EBT Excluding Unusual Items | 57.6 | -42.85 | -245.62 | 227.35 | 196.46 | 177.67 |
| Impairment of Goodwill | - | - | -21.42 | - | - | - |
| Gain (Loss) on Sale of Investments | 3.29 | 3.29 | - | - | - | - |
| Asset Writedown | - | - | -3 | - | - | - |
| Pretax Income | 60.9 | -39.56 | -270.03 | 227.35 | 196.46 | 177.67 |
| Income Tax Expense | -1.56 | -1.51 | 2.6 | 53.48 | 48.49 | 42.54 |
| Earnings From Continuing Operations | 62.45 | -38.04 | -272.64 | 173.88 | 147.97 | 135.13 |
| Minority Interest in Earnings | -0.06 | -0.05 | -0.01 | -0.04 | -0.04 | -0 |
| Net Income | 62.4 | -38.1 | -272.65 | 173.84 | 147.93 | 135.13 |
| Net Income to Common | 62.4 | -38.1 | -272.65 | 173.84 | 147.93 | 135.13 |
| Net Income Growth | - | - | - | 17.51% | 9.47% | - |
| Shares Outstanding (Basic) | 570 | 570 | 564 | 572 | 577 | 577 |
| Shares Outstanding (Diluted) | 570 | 570 | 564 | 572 | 577 | 577 |
| Shares Change (YoY) | 1.17% | 1.12% | -1.46% | -0.88% | - | - |
| EPS (Basic) | 0.11 | -0.07 | -0.48 | 0.30 | 0.26 | 0.23 |
| EPS (Diluted) | 0.11 | -0.07 | -0.48 | 0.30 | 0.26 | 0.23 |
| EPS Growth | - | - | - | 17.09% | 11.40% | - |
| Free Cash Flow | -22.5 | -86.76 | -44.44 | 129.63 | 44.44 | 38.88 |
| Free Cash Flow Per Share | -0.04 | -0.15 | -0.08 | 0.23 | 0.08 | 0.07 |
| Dividend Per Share | - | - | - | 0.107 | 0.069 | - |
| Dividend Growth | - | - | - | 54.70% | - | - |
| Gross Margin | 63.23% | 62.14% | 56.21% | 76.98% | 79.74% | 78.55% |
| Operating Margin | 16.52% | 2.31% | -34.67% | 32.12% | 34.26% | 42.17% |
| Profit Margin | 9.68% | -7.33% | -51.83% | 23.83% | 24.89% | 31.39% |
| Free Cash Flow Margin | -3.49% | -16.69% | -8.45% | 17.77% | 7.48% | 9.03% |
| EBITDA | 108.58 | 16.6 | -175.19 | 237.89 | 206.04 | 183.49 |
| EBITDA Margin | 16.84% | 3.19% | -33.31% | 32.61% | 34.67% | 42.62% |
| D&A For EBITDA | 2.03 | 4.57 | 7.2 | 3.54 | 2.42 | 1.94 |
| EBIT | 106.55 | 12.03 | -182.39 | 234.35 | 203.62 | 181.55 |
| EBIT Margin | 16.52% | 2.31% | -34.67% | 32.12% | 34.26% | 42.17% |
| Effective Tax Rate | - | - | - | 23.52% | 24.68% | 23.94% |
| Advertising Expenses | - | - | - | - | - | 7.54 |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.